Published in Gene Therapy Weekly, February 2nd, 1998
Zenapax is a genetically engineered drug used in combination with other anti-rejection medications, significantly reduces the risk of acute rejection episodes in patients who undergo kidney transplants. Because Zenapax is a humanized monoclonal antibody, the body is less likely to recognize it as foreign.
Thus, its efficacy is less likely to be limited by the body's natural response to non-human antibodies. The study found that Zenapax reduces the incidence of kidney rejection episodes to as low as 22 percent,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.